Today's News

Vancouver, BC, January 8, 2015--(T-Net)--BC life sciences company Aequus Pharmaceuticals Inc. has filed a preliminary long form prospectus for the qualification of the distribution of 7,618,780 units issuable at a price of $0.55 per special warrant.

Aequus intends to apply to list the common shares and the underlying warrants on the TSX Venture Exchange, to raise net proceeds of $3.8 million.

Aequus Pharmaceuticals was founded in 2013 and recently closed a $4.2 Million private placement financing in November 2014, as reported earlier on T-Net, as well asan earlier $1.2 million equity financing in September 2013.

Aequus Pharmaceuticals Inc is a Vancouver-based life sciences company, focused on enhancing delivery methods for approved drugs and select consumer products that are limited by non-compliance, high frequency dosing, first-pass metabolism side effects, painful injections, or where the commercial presentation can be improved by making a long acting alternative available.

The Chairman and CEO of Aequus Pharmaceuticals, Doug Janzen, was previously President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that completed an $800M licensing deal with Merck. He currently is also the Co-Founder and Managing Director of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies.

Aequus Pharmaceutical's pipeline is strategically focused on reformulated products which leverage their internal and partner expertise in transdermal delivery. Their lead programs are being developed for the potential treatment of multiple CNS disorders.

The Company has used, or intends to use, the net proceeds of the Offering of $3,792,059.17, plus the net proceeds of the December 2014 Financing (as defined below) of $332,750, minus its estimated current working capital deficiency (excluding the net proceeds of the Offering) as of November 30,2014 of $533,750, as follows:

AQS-1301 formulation optimization $450,000

AQS-1301Phase Ia Proof of Concept study $300,000

AQS-1301 Phase Ib Bioequivalence study $600,000

AQS-1301 Phase II Preparation $100,000

AQS-1302 Research and preclinical studies $350,000

Patent conversions and applications $100,000

Business development, general administration andworking capital for twenty four months $1,691,059

Total use of proceeds $3,591,059

Estimated net proceeds of the Offering $3,792,059.17

Estimated net proceeds of the December 2014 Financing $332,750

Estimated current working capital (1) $(553,750)

Estimated total working capital $3,591,059

Aequus expects to commercialize AQS-1301 if approved by the FDA and other relative regulatory bodies for comercial sales, via a third party commercial partner or partners.

The Chairman and CEO of Aequus Pharmaceuticals, Doug Janzen, was previously President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that completed an $800M licensing deal with Merck. He currently is also the Co-Founder and Managing Director of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc is a Vancouver-based company, focused on enhancing delivery methods for approved drugs and select consumer products that are limited by non-compliance, high frequency dosing, first-pass metabolism side effects, painful injections, or where the commercial presentation can be improved by making a long acting alternative available.